Clinical Performance Evaluation of a SARS-CoV-2 Rapid Antibody Test for Determining Past Exposure to SARS-CoV-2

Peter Findeisen[a], Hugo Stiegler[b], Eloisa Lopez-Calle[c], Tanja Schneider[d], Eva Urlaub[c], Johannes Hayer[c], Claudia Zemmrich[e,f#]

[a]MVZ Labor Dr. Limbach & Kollegen GbR, Heidelberg, Germany

[b]MVZLM - Medizinisches Versorgungszentrum für Labormedizin und Mikrobiologie Ruhr GmbH, 45138 Essen, Germany

[c]Roche Diagnostics GmbH, Mannheim, Germany

[d]Roche Diagnostics GmbH, Penzberg, Germany

[e#]Institute for Pharmacology and Preventive Medicine, Menzelstrasse 21, 15831 Mahlow, Germany

[f]Roche Diagnostics International Ltd. Rotkreuz, Switzerland

Corresponding author: Claudia Zemmrich, Institute for Pharmacology and Preventive Medicine, Menzelstrasse 21, 15831 Mahlow, Germany, claudia.zemmrich@ippmed.de

Running title: Performance of a SARS-CoV-2 rapid antibody test

Abstract

The true prevalence and population seropositivity of SARS-CoV-2 infection remains unknown, due to the number of asymptomatic infections and limited access to high-performance antibody tests. To control the COVID-19 pandemic it is crucial to understand the true seroprevalence, but not every region has access to extensive centralized PCR and serology testing. Currently available rapid antibody tests lack the accuracy needed for recommendation by health authorities. To fill this gap, we analyzed and validated the clinical performance of a new point-of-care SARS-CoV-2 Rapid Antibody Assay, a chromatographic immunoassay for qualitative detection of IgM/IgG antibodies for use in near-patient settings. Analysis was performed using 42 Anti-SARS-Cov-2 positive (CoV+) and 92 Anti-SARS-Covid-2 negative (CoV-) leftover samples from before December 2019, using the Elecsys® Anti-SARS-CoV-2 as the reference assay. Analytical specificity was tested using leftover samples from individuals with symptoms of common cold collected before December 2019. The SARS-CoV-2 Rapid Antibody Test was 100.0% (95% CI 91.59–100.00) sensitive and 96.74% (95% CI 90.77–99.32) specific with an assay failure rate of 0.00%. No cross-reactivity was observed against the common cold panel. Method comparison was additionally conducted by two external laboratories, using 100 CoV+/275 CoV- samples, also comparing whole blood versus plasma matrix. The comparison demonstrated for plasma 96.00% positive/96.36% negative percent agreement with the Elecsys Anti-SARS-CoV-2 and overall 99.20% percent agreement between whole blood and EDTA plasma. The SARS-CoV-2 Rapid Antibody Test demonstrated similar clinical performance to the manufacturer's data and to a centralized automated immunoassay, with no cross-reactivity to common cold panels.

Key words: SARS-CoV-2, rapid antibody test, past exposure

42 **Introduction**

43 The global COVID-19 pandemic created an urgent unmet clinical need to investigate reliable
44 diagnostic tools for patients, as well as understand the extent of exposure and spread of
45 infection among wider populations (1-3). Acute diagnosis of the COVID-19 infection is based on
46 identification of viral RNA via PCR from swab samples, which is detectable from symptom onset
47 for approximately four weeks (2, 4). As is known from localized testing during outbreaks, many
48 people who are infected with the virus do not present with any clinical symptoms – current
49 estimates suggest around 30% of seropositive individuals are asymptomatic (5-7). Those
50 individuals carry the virus and potentially spread it to others, who may react with a severe
51 COVID-19 disease (8). No region in the world can perform PCR testing of every patient with
52 common cold symptoms or who has had contact with a suspected COVID-19 patient. In addition
53 to clinical testing of individuals with suspected COVID-19 for direct virus detection, surveillance
54 strategies need to combine several diagnostic techniques to monitor disease kinetics in wider
55 populations (2, 9). To control the pandemic, it seems crucial to investigate who has already had
56 an infection and has developed antibodies as an immune response, and vice versa, who is still
57 vulnerable to an infection (10-14).

58 Antibody tests are not intended to diagnose an acute COVID-19 infection, more specific
59 diagnostic methods should be performed to obtain this (2). Ongoing research on the level and
60 duration of immunity of seropositive persons will add further value to the clinical and
61 epidemiological interpretation of positive antibody testing results. Preliminary data suggest
62 that high affinity antibody tests show good correlation with neutralizing activity (15).

63 Based on current evidence, immunoglobulin M (IgM) antibodies are detectable within 5 days
64 after symptom onset and immunoglobulin G (IgG) antibodies within 5–7 days (4, 16-23).
65 Depending on the applied method, seroconversion is observed after a median of 10–13 days
66 after symptom onset for IgM and 12–14 days for IgG, and maximum for both is reached after 2
67 weeks (4, 16, 19-26). Individual levels and kinetics of both IgM and IgG are highly variable,
68 which is why simultaneous detection of both is recommended.

69 Currently available rapid antibody tests require improved accuracy before being recommended
70 by competent authorities and used by healthcare professionals (HCPs) in the wider population
71 (2, 3). The US Food and Drug Administration (FDA) released technical requirements for antibody
72 tests on April 4, 2020, that include a specificity of ≥ 95% and cross-reactivity testing for
73 common cold and other coronaviruses (27). There are different high-throughput Anti-SARS-
74 CoV-2 antibody tests available; the assay selected as the reference for our test (Elecsys Anti-
75 SARS-CoV-2 Immunoassay) is based on electrochemiluminescence (ECLIA), using a double-
76 antigen sandwich test principle and a recombinant protein representing the antigen for the
77 determination of antibodies to SARS-CoV-2, namely the nucleocapsid protein (N) (28). It
78 provides a qualitative result with a sensitivity of 100.0% (95% CI 88.10–100.0) at ≥ 14 days after
79 PCR confirmation and a specificity of 99.81% (95% CI 99.65–99.91) (28).
80

81 Rapid tests, also called point-of-care (PoC) tests, combine immunoassay and chromatography
82 for a qualitative detection of antibodies. The selected test *(Anti-SARS-CoV-2 Rapid Antibody*
83 *Test [SD Biosensor, Chungcheongbuk-do, Republic of Korea])* is a CE marked lateral flow assay
84 displaying a visual 'yes/no' answer for the selective detection of specific IgG and/or IgM
85 antibodies to SARS-CoV-2, with two separate colored bands for IgG and IgM (29). The
86 manufacturer states the specificity is 98.65% and sensitivity beyond 14 days after symptom

87 onset of 99.03%, tested on 103 PCR-confirmed CoV+ and 222 CoV- samples (29). The samples
88 had also been tested for early sensitivity between 7 and 14 days after symptom onset with a
89 result of 92.59%. SD Biosensor has performed several cross-reactivity studies involving
90 numerous specimens, including influenza A and B.
91
92 In this study series, we further validated and extended the manufacturers' clinical performance
93 and cross-reactivity data and externally performed a matrix and method comparison to gain
94 additional data on the overall assay performance.

95 **Materials and Methods**

96 ***The assay***

97 The assay ***(Figure 1)*** needs 10 µl human serum or plasma, or 20 µl whole venous or capillary
98 blood sample to be filled into the preformed well of the test device. Three pre-coated lines
99 mark the "C" control line, and the "G" and "M" test lines for IgG and IgM. Monoclonal chicken
100 IgY antibody is coated on the "C" region, and monoclonal anti-human IgG antibody and
101 monoclonal anti-human IgM antibody are coated on the "G" and "M" test line region. During
102 the test, SARS-CoV-2-specific antibodies in the sample interact with recombinant SARS-CoV-2
103 protein (nucleocapsid and spike protein) conjugated with colloidal gold particles forming
104 antibody–antigen gold particle complexes. This complex migrates on the membrane via
105 capillary action until the "M" and "G" test line, where it will be captured by the monoclonal
106 anti-human IgG antibody or monoclonal anti-human IgM antibody. A violet test line would be
107 visible in the result window if SARS-CoV-2-specific antibodies are present in the sample. The
108 intensity of the colored test line varies depending upon the amount of SARS-CoV-2 antibodies

109 present in the sample. Even if the color is faint, the test result should be interpreted as a
110 positive result. The control line is used as procedural control and should always appear if the
111 test procedure is performed properly and the test reagents are working.

112 ***Study design***

113 A performance analysis was conducted at Roche Diagnostics (Penzberg, Mannheim, Germany)
114 using 42 Elecsys Anti-SARS-CoV-2 confirmed CoV+ and 92 leftover samples from healthy donors,
115 collected before December 2019 and additionally confirmed by the Elecsys Anti-SARS-CoV-2
116 CoV- (56 lithium heparin plasma, 36 EDTA plasma). Cross-reactivity testing was conducted with
117 18 samples from individuals expressing signs and symptoms of common cold (i.e. sore throat,
118 cough, fever) collected before December 2019. Additional matrix equivalence and read-out
119 time analysis captured 159 Elecsys referenced CoV- samples, consisting of 55 heparin plasma,
120 55 EDTA plasma and 49 serum samples.

121 Additionally, an independent comparison was performed with matched EDTA plasma and
122 whole blood samples from a total of 375 anonymized leftover samples at two external testing
123 sites. In total, 100 samples tested positive for SARS-CoV-2 antibodies by the Elecsys anti–SARS-
124 CoV2 immunoassay and 275 negative samples (25 CoV+/75 negative- subjects at MVZLM Ruhr
125 GmbH, Essen and 75 CoV+/200 negative subjects at MVZ Labor Dr. Limbach & Kollegen GbR
126 Heidelberg). No information on PCR result or time of sample collection related to symptom
127 onset was available. All samples were analyzed with the Anti-SARS-CoV-2 Rapid Antibody Assay
128 and results were compared directly with the EDTA plasma sample from the Elecsys Anti-SARS-
129 CoV-2 Assay (see Figure 1 for workflow).

130 All investigations were performed according in a single determination and according to the
131 manufacturer's instructions for use.

132 ***Statistical analyses***

133 For sensitivity and specificity, point estimates and 95% CI values were calculated. To determine
134 positive and negative percent agreement (PPA and NPA), the Elecsys Anti-SARS-CoV-2 result
135 was used as comparator: »Non-reactive« (cut off index [COI] < 1.0) was a negative result and
136 »Reactive« (COI ≥ 1.0) a positive result. The rapid test was considered positive in case either IgG
137 or IgM showed a colored line, even if the line was faint. The Clopper–Pearson exact method
138 was used for the calculation of the two-sided 95% confidence intervals (CIs).

139 ***Ethics and conformity declaration***

140 The study was conducted in accordance with applicable regulations, including relevant
141 European Union directives and regulations, and the principles of the Declaration of Helsinki. All
142 samples were anonymized leftover specimens. For the samples tested at Roche Diagnostics, a
143 statement was obtained from the Ethics Committee of the Landesärztekammer Bayern
144 confirming that there are no objections against the transfer and the coherent use of the
145 anonymized leftover samples. For the samples tested in MVZLM Ruhr GmbH (Essen) and at
146 MVZ Labor Dr. Limbach & Kollegen GbR (Heidelberg) no ethics committee vote is required in
147 accordance with MPG (Medizinproduktegesetz Deutschland).

148

149 ***Data availability***

150 Qualified researchers may request access to individual patient level data through the clinical
151 study data request platform (https://vivli.org/). Further details on Roche's criteria for eligible
152 studies are available here: https://vivli.org/members/ourmembers/. For further details on
153 Roche's Global Policy on the Sharing of Clinical Information and how to request access to

154 related clinical study documents, see here:

155 https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_tria

156 ls/our_commitment_to_data_sharing.htm.

157 **Results**

158 ***Clinical performance evaluation***

159 The assay presented a qualitative visual test result without the need for a read-out instrument

160 like other rapid antibody devices on the market. Some lines were quite faint, and according to

161 manufacturer's instruction they have been interpreted as a positive result. Handling was easy

162 with one sample-transfer step and three drops of buffer dropped into the well after the blood

163 sample; the results read at 10–15 minutes. Except quality control material, lancets and a

164 transferring pipette for 10 µl, everything needed to conduct the test was included into the test

165 package. All test cassettes were correctly assembled, opening the foil pouch was easy without

166 danger of destroying the desiccant and no membranes were scratched.

167 A total of 42 left-over samples with prior Elecsys-confirmed positive SARS-CoV-2 antibody

168 detection were included in the sensitivity analysis. The overall sensitivity was 100.0% (95 % CI

169 91.59–100.0) (Table 1). A total of 92 samples from healthy donors before December 2019

170 presented an overall specificity of 96.74% (95% CI 90.77–99.32) with no difference between

171 EDTA and lithium-heparin plasma: 97.22% (95% CI: 85.47–99.93)/96.43% (95% CI 87.69–99.56).

172 An additional matrix evaluation and read-out time analysis was performed with 159 SARS-CoV-2

173 negative samples to confirm equal results throughout the pre-defined read-out time window.

174 At read out times ≤10 minutes specificity was slightly higher versus at 15 minutes (Table 2),

175 however detectable signals were 'weaker' or less well defined at ≤10 minutes compared with

176 15 minutes read out time. No relevant performance differences were noticed between serum,
177 heparin and EDTA plasma (Table 2).

178 Cross-reactivity was tested at 18 samples from a common cold panel, collected before
179 December 2019 without further information on the exact pathogens of the specimens. For all
180 18 measurements, a colored control line was obtained, indicating that the test worked
181 properly. On the test lines for IgG and IgM no color appeared, thus leading to a negative result
182 and resulting in a specificity of 100.0% (95 % CI 81.47–100.0%). The results demonstrated that
183 the test is not reacting with antibodies directed against related pathogens from common cold
184 infections.

185 ***External method and matrix comparison***

186 Total results for both testing methods (plasma/whole blood samples) were 96.00% (95 % CI
187 90.07–98.90) / 94.00% (95% CI 87.40–97.77) for positive percent agreement rate and 96.36%
188 (95% CI 93.41–98.24) / 96.00 % (95% CI 92.96–97.99) for negative percent agreement rate. The
189 sample numbers per matrix and per immunoglobulin class for the samples confirmed by the
190 Elecsys test and the numbers differing from the Elecsys result are summarized in Table 3. The
191 overall percent agreement rate between whole blood and EDTA plasma was 99.20% (95% CI
192 97.68–99.83), the positive/negative percent agreement rates for whole blood versus EDTA
193 plasma were 98.11 % (95% CI 93.35–99.77) / 99.63 (95% CI 97.95–99.99).

194 A total of 10 EDTA samples and 11 whole blood samples were detected antibody positive by the
195 Anti-SARS-CoV-2 Rapid Antibody Assay but antibody negative by the Elecsys assay, see Table 4a
196 for the respectively detected immunoglobulin classes and the respective signal intensity on the
197 11 rapid tests. 96 plasma and 94 whole blood samples out of 100 Elecsys-positive samples were
198 detected positive by the rapid test, see Table 4b for the respective immunoglobulin classes and

199 signal intensity of the six rapid test results. The matrix comparison for the Anti-SARS-CoV-2
200 Rapid Antibody Assay found of 106 plasma samples with an antibody positive test result,
201 included two samples which had negative tests results with whole blood. One out of 269
202 negative test results on the rapid test with plasma displayed a positive result with whole blood.

203 **Discussion**

204 The COVID-19 pandemic has created an urgent need for antibody testing of large populations to
205 determine seroprevalence and potential immunity, which will be of more importance if more
206 conclusive scientific data on correlation between these factors become available (2, 3, 26, 30,
207 31). The anticipated need for high testing capacities in PoC settings outside of large hospitals,
208 calls for the development and validation of high-performance rapid antibody tests as reliable
209 diagnostic instruments, in addition to the centralized antibody tests available. The evaluated
210 Anti-SARS-CoV-2 Rapid Antibody Test complies with the acceptance criteria, defined by the FDA
211 EUA on April 4, 2020, for SARS-CoV-2 antibody test developments (27). Our internal clinical
212 performance evaluation confirmed the manufacturers' reported clinical sensitivity of the test
213 with an uncharacterized cohort of antibody positive samples from a population with unknown
214 time from symptom onset, which may reflect the typical clinical scenario for the test indication.
215 The external comparison confirmed high agreement of both the Elecsys assay and the Anti-
216 SARS-CoV-2 Rapid Antibody Test, also with no confirmed PCR result and time of sampling from
217 symptom onset unknown. For both the internal and external evaluation, samples could be
218 mixed, with some collected early after symptom onset. Both tests claim less than 100 %
219 sensitivity <14 days after symptom onset (28, 29). The Elecsys Anti-SARS-CoV-2 Antibody Test
220 measures high-affinity IgG/IgM antibodies directed at the nucleocapsid antigen, with an

221 excellent sensitivity of 100.0% (95% CI 88.1–100.0) at ≥ 14 days after PCR confirmation (28). The
222 rapid test has been developed detecting both nucleocapsid- and spike protein-associated
223 antibodies to increase test accuracy compared with centralized serological assays, which
224 typically perform better than rapid tests. (29). A limitation of this study is that samples were
225 not differentiated according to time of collection after symptom onset, as such some of the
226 false positive samples might actually be true positives, but were not detected by the Elecsys
227 assay and most likely indicate an early antibody response with low affinity antibodies. For SARS-
228 CoV-2 tests high specificity is a priority, particularly in low prevalence settings (30), as such it
229 would be interesting to further evaluate the interpretation of the low positive samples at the
230 rapid test, particularly for samples that were IgM positive only, to determine if these reflect
231 non-specific binding, or true early detection. Further assessment with serial samples taken from
232 COVID-19 patients from early infection phase onwards will help to better understand this.

233 The investigated Anti-SARS-CoV-2 Rapid Antibody Test provided readily evaluable results,
234 regardless of sample type (whole blood or EDTA plasma) and independent of any read-out time
235 between 10 and 15 minutes, as stated in the instructions for use. Those positive practical
236 aspects could enable potential use outside medical environments. The assay is currently
237 intended for professional use in laboratory and PoC environments as an aid in identifying
238 individuals with an adaptive immune response to SARS-CoV-2, indicating prior infection.

239 In these studies, the SARS-CoV-2 Rapid Antibody Test demonstrates excellent clinical
240 performance without cross-reactivity to common cold samples and results comparable to data
241 of an automated high-performance immunoassay (Elecsys). Our data confirm and extend the
242 manufacturers' performance data and add further details on matrix and method comparisons.
243 Available data support its use as a reliable diagnostic instrument for SARS-CoV-2 IgM and IgG

antibody detection in near-patient settings with potential extended usability outside medical environments.

Acknowledgements

The authors would like to acknowledge the contributions of Rabea Held, Regina Draude, Marcus Pollok (Roche Diagnostics GmbH, Mannheim, Germany) for testing, data acquisition in the laboratory and preliminary data analysis. In addition, thanks to Imola Szebenyi, Oscar Gutierrez-Sanz, Miriam Hübner, Ludwig Pollich, Nicolai Bluthardt, Andreas Aristow (Roche Diagnostics GmbH, Penzberg, Germany) for the measurements of the clinical and cross-reactivity samples as part of the study conducted at Roche Diagnostics. Thanks to John Burden (Roche Diagnostics International Ltd. Rotkreuz, Switzerland), Sven Groesgen (Roche Diagnostics GmbH, Mannheim, Germany) and Christine Jung (Roche Diagnostics GmbH, Penzberg, Germany) for planning, set-up and analysis of the external evaluation. The authors would also like to acknowledge Matthias Metz and Daria Glukhova for conducting the measurements with the Elecsys SARS-CoV-2 method as part of the study at Roche Diagnostics.

Conflicts of interest/financial disclosures

Eloisa Lopez-Calle, Tanja Schneider, Eva Urlaub, Johannes Hayer, are all employees of Roche Diagnostics. Claudia Zemmrich works as a freelance contractor for Roche Diagnostics.

References

1. The World Health Organization. 2020. Immunity passports in the context of COVID-19. https://www.who.int/news-room/commentaries/detail/immunity-passports-in-the-context-of-covid-19. Accessed July 2020.

265 2. The European Centre for Disease Prevention and Control. 2020. Diagnostic testing and
266 screening for SARS-CoV-2. https://www.ecdc.europa.eu/en/covid-19/latest-
267 evidence/diagnostic-testing. Accessed July 2020.
268 3. The US Centers for Disease Prevention and Control. 2020. Interim guidelines for COVID-19
269 antibody testing. https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antibody-tests-
270 guidelines.html. Accessed June 2020.
271 4. Sethuraman N, Jeremiah SS, Ryo A. 2020. Interpreting diagnostic tests for SARS-CoV-2. JAMA
272 doi:10.1001/jama.2020.8259.
273 5. Pollan M, Perez-Gomez B, Pastor-Barriuso R, Oteo J, Hernan MA, Perez-Olmeda M, Sanmartin JL,
274 Fernandez-Garcia A, Cruz I, Fernandez de Larrea N, Molina M, Rodriguez-Cabrera F, Martin M,
275 Merino-Amador P, Leon Paniagua J, Munoz-Montalvo JF, Blanco F, Yotti R, Group E-CS. 2020.
276 Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based
277 seroepidemiological study. Lancet doi:10.1016/S0140-6736(20)31483-5.
278 6. Sandri MT, Azzolini E, Torri V, Carloni S, Tedeschi M, Castoldi M, Mantovani A, Rescigno M. 2020.
279 IgG serology in health care and administrative staff populations from 7 hospital representative
280 of different exposures to SARS-CoV-2 in Lombardy, Italy. medRxiv
281 doi:10.1101/2020.05.24.20111245:2020.05.24.20111245.
282 7. Mizumoto K, Kagaya K, Zarebski A, Chowell G. 2020. Estimating the asymptomatic proportion of
283 coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship,
284 Yokohama, Japan, 2020. Euro Surveill 25;(10):2000180
285 8. European Centre for Disease Prevention and Control. 2020. Transmission of COVID-19.
286 https://www.ecdc.europa.eu/en/covid-19/latest-evidence/transmission. Accessed July 2020.
287 9. The World Health Organization. 2020. Surveillance strategies for COVID-19 human infection:
288 interim guidance. https://www.who.int/publications/i/item/surveillance-strategies-for-covid-19-
289 human-infection. Accessed July 2020.

290 10. Althoff KN, Coburn SB, Nash D. 2020. Contact tracing: Essential to the public health response
291 and our understanding of the epidemiology of COVID-19. Clin Infect Dis
292 doi:10.1093/cid/ciaa757.
293 11. Fiore VG, DeFelice N, Glicksberg BS, Perl O, Shuster A, Kulkarni K, O'Brien M, Pisauro MA, Chung
294 D, Gu X. 2020. Containment of future waves of COVID-19: simulating the impact of different
295 policies and testing capacities for contact tracing, testing, and isolation. medRxiv
296 doi:10.1101/2020.06.05.20123372.
297 12. MacIntyre CR. 2020. Case isolation, contact tracing, and physical distancing are pillars of COVID-
298 19 pandemic control, not optional choices. Lancet Infect Dis doi:10.1016/S1473-3099(20)30512-
299 0.
300 13. Sen-Crowe B, McKenney M, Elkbuli A. 2020. COVID-19 laboratory testing issues and capacities as
301 we transition to surveillance testing and contact tracing. Am J Emerg Med
302 doi:10.1016/j.ajem.2020.05.071.
303 14. Steinbrook R. 2020. Contact Tracing, Testing, and Control of COVID-19-Learning From Taiwan.
304 JAMA Intern Med doi:10.1001/jamainternmed.2020.2072.
305 15. Wu F, Wang A, Liu M, Wang Q, Chen J, Xia S, Ling Y, Zhang Y, Xun J, Lu L, Jiang S, Lu H, Wen Y,
306 Huang J. 2020. Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient
307 cohort and their implications. medRxiv
308 doi:10.1101/2020.03.30.20047365:2020.03.30.20047365.
309 16. Guo L, Ren L, Yang S, Xiao M, Chang, Yang F, Dela Cruz CS, Wang Y, Wu C, Xiao Y, Zhang L, Han L,
310 Dang S, Xu Y, Yang Q, Xu S, Zhu H, Xu Y, Jin Q, Sharma L, Wang L, Wang J. 2020. Profiling early
311 humoral response to diagnose novel coronavirus disease (COVID-19). Clin Infect Dis
312 doi:10.1093/cid/ciaa310.
313 17. Liu L, Liu W, Wang S, Zheng S. 2020. A preliminary study on serological assay for severe acute
314 respiratory syndrome coronavirus 2 (SARS-CoV-2) in 238 admitted hospital patients. medRxiv
315 doi:10.1101/2020.03.06.20031856:2020.03.06.20031856.

316 18. Long Q-X, Deng H-J, Chen J, Hu J, Liu B-Z, Liao P, Lin Y, Yu L-H, Mo Z, Xu Y-Y, Gong F, Wu G-C,
317 Zhang X-C, Chen Y-K, Li Z-J, Wang K, Zhang X-L, Tian W-G, Niu C-C, Yang Q-J, Xiang J-L, Du H-X, Liu
318 H-W, Lang C, Luo X-H, Wu S-B, Cui X-P, Zhou Z, Wang J, Xue C-J, Li X-F, Wang L, Tang X-J, Zhang Y,
319 Qiu J-F, Liu X-M, Li JJ, Zhang D-C, Zhang F, Cai X-F, Wang D, Hu Y, Ren J-H, Tang N, Liu P, Li Q,
320 Huang A-L. 2020. Antibody responses to SARS-CoV-2 in COVID-19 patients: the perspective
321 application of serological tests in clinical practice. medRxiv
322 doi:10.1101/2020.03.18.20038018:2020.03.18.20038018.
323 19. Lou B, Li T, Zheng S, Su Y, Li Z, Liu W, Yu F, Ge S, Zou Q, Yuan Q, Lin S, Hong C, Yao X, Zhang X, Wu
324 D, Zhou G, Hou W, Li T, Zhang Y, Zhang S, Fan J, Zhang J, Xia N, Chen Y. 2020. Serology
325 characteristics of SARS-CoV-2 infection since the exposure and post symptoms onset. medRxiv
326 doi:10.1101/2020.03.23.20041707:2020.03.23.20041707.
327 20. Okba NMA, Marcel AM, Wentao L, Chunyan W, Corine HG, Victor MC, Mart ML, Reina SS, Erwin
328 de B, Felicity DC, Yazdan Y, Quentin Le H, Diane D, Nadhira H-F, Chantal BEMR, Berend-Jan B,
329 Christian D, Marion PGK, Bart LH. 2020. Severe acute respiratory syndrome coronavirus
330 2−Specific antibody responses in coronavirus disease 2019 patients. Emerging Infectious Disease
331 journal 26(7):1478–88..
332 21. Tan W, Lu Y, Zhang J, Wang J, Dan Y, Tan Z, He X, Qian C, Sun Q, Hu Q, Liu H, Ye S, Xiang X, Zhou
333 Y, Zhang W, Guo Y, Wang X-H, He W, Wan X, Sun F, Wei Q, Chen C, Pan G, Xia J, Mao Q, Chen Y,
334 Deng G. 2020. Viral Kinetics and Antibody Responses in Patients with COVID-19. medRxiv
335 doi:10.1101/2020.03.24.20042382:2020.03.24.20042382.
336 22. To KK-W, Tsang OT-Y, Leung W-S, Tam AR, Wu T-C, Lung DC, Yip CC-Y, Cai J-P, Chan JM-C, Chik
337 TS-H, Lau DP-L, Choi CY-C, Chen L-L, Chan W-M, Chan K-H, Ip JD, Ng AC-K, Poon RW-S, Luo C-T,
338 Cheng VC-C, Chan JF-W, Hung IF-N, Chen Z, Chen H, Yuen K-Y. 2020. Temporal profiles of viral
339 load in posterior oropharyngeal saliva samples and serum antibody responses during infection
340 by SARS-CoV-2: an observational cohort study. The Lancet Infectious Diseases 20:565-574.

341 23. Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, Wang X, Yuan J, Li T, Li J, Qian S, Hong C, Wang F, Liu
342 Y, Wang Z, He Q, Li Z, He B, Zhang T, Fu Y, Ge S, Liu L, Zhang J, Xia N, Zhang Z. 2020. Antibody
343 responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin Infect Dis
344 doi:10.1093/cid/ciaa344.
345 24. Amanat F, Stadlbauer D, Strohmeier S, Nguyen T, Chromikova V, McMahon M, Jiang K, Asthagiri-
346 Arunkumar G, Jurczyszak D, Polanco J, Bermudez-Gonzalez M, Kleiner G, Aydillo T, Miorin L,
347 Fierer D, Lugo LA, Milunka Kojic E, Stoever J, Liu STH, Cunningham-Rundles C, Felgner PL,
348 Caplivski D, Garcia-Sastre A, Cheng A, Kedzierska K, Vapalahti O, Hepojoki J, Simon V, Krammer
349 F, Moran T. 2020. A serological assay to detect SARS-CoV-2 seroconversion in humans. medRxiv
350 doi:10.1101/2020.03.17.20037713:2020.03.17.20037713.
351 25. Xiang F, Wang X, He X, Peng Z, Yang B, Zhang J, Zhou Q, Ye H, Ma Y, Li H, Wei X, Cai P, Ma WL.
352 2020. Antibody detection and dynamic characteristics in patients with COVID-19. Clin Infect Dis
353 doi:10.1093/cid/ciaa461.
354 26. Zhang J, Liu J, Li N, Liu Y, Ye R, Qin X, Zheng R. 2020. Serological detection of 2019-nCoV respond
355 to the epidemic: A useful complement to nucleic acid testing. medRxiv
356 doi:10.1101/2020.03.04.20030916:2020.03.04.20030916.
357 27. Administration UFaD. 2020. Policy for coronavirus disease-2019 tests during the public health
358 emergency (Revised). https://www.fda.gov/regulatory-information/search-fda-guidance-
359 documents/policy-coronavirus-disease-2019-tests-during-public-health-emergency-revised.
360 28. Roche Diagnostics GmbH. 2020. Elecsys Anti-SARS-CoV-2 Method Sheet.
361 29. SD Biosensor. 2020. SARS-CoV-2 Rapid Antibody Test Method Sheet.
362 30. Ozcurumez MK, Ambrosch A, Frey O, Haselmann V, Holdenrieder S, Kiehntopf M, Neumaier M,
363 Walter M, Wenzel F, Wolfel R, Renz H, Chemistry C-TFotGSfC, Laboratory M. 2020. SARS-CoV-2
364 antibody testing-questions to be asked. J Allergy Clin Immunol 146:35-43.
365 31. Theel ES, Slev P, Wheeler S, Couturier MR, Wong SJ, Kadkhoda K. 2020. The Role of Antibody
366 Testing for SARS-CoV-2: Is There One? J Clin Microbiol doi:10.1128/JCM.00797-20.

368 **Table 1. Performance data of the manufacturer, internal clinical performance test, matrix equivalence test and external method comparison**

	SD Biosensor data**, % (95% CI)	Internal test, % (95% CI)	Matrix evaluation, % (95% CI)	External comparison (95% CI)
Samples tested, n	195+ / 222-	42+ / 92-	159-	100+ / 275-
Reference method	PCR	Elecsys® Anti-SARS-CoV-2 Antibody Assay	Elecsys® Anti-SARS-CoV-2 Antibody Assay	*n.a.*
Specificity versus Reference method	98.65 (96.10–99.72)	96.74 (90.77–99.32)	96.23 (91.97–98.60)	96.00*** (90.07–98.90)
Sensitivity versus Reference method • 7–14 days*	92.59 (82.11–97.94)			
• > 14 days*	99.03 (94.71–99.98)			
• All time periods		100 (91.59–100.00)	n.a.	96.36*** (93.41–98.24)

369

370 n.a. not applicable; +/-, positive/negative for SARS-CoV-2 determined by respective reference method

371 *Post symptom onset; **according to Anti-SARS-CoV-2 Rapid Antibody Assay Method sheet; ***positive/negative percent agreement with

372 Elecsys Anti-SARS-CoV-2 in EDTA plasma, data in italics as generated by comparative analysis, not clinical performance analysis

373

374 **Table 2. Matrix evaluation and read-out time analysis**

		Read out time			
		8 mins	**10 mins**	**12 mins**	**15 mins**
Total	**Number of samples test (negative)**	159	159	159	159
	False positive	4	5	6	6
	Specificity % (95% CI)	97.48 (93.68–99.31)	96.86 (92.81–98.97)	96.23 (91.97–98.60)	96.23 (91.97–98.60)
Serum	**Number of samples test (negative)**	49	49	49	49
	False positive	1	2	2	2
	Specificity % (95% CI)	97.96 (89.15–99.95)	95.92 (86.02–99.50)	95.92 (86.02–99.50)	95.92 (86.02–99.50)
Heparin plasma	**Number of samples test (negative)**	55	55	55	55
	False positive	1	1	2	2
	Specificity % (95% CI)	98.18 (90.28–99.95)	98.18 (90.28–99.95)	96.36 (87.47–99.56)	96.36 (87.47–99.56)
EDTA plasma	**Number of samples test (negative)**	55	55	55	55
	False positive	2	2	2	2
	Specificity % (95% CI)	96.36 (87.47–99.56)	96.36 (87.47–99.56)	96.36 (87.47–99.56)	96.36 (87.47–99.56)

375

376 **Table 3. External comparison to Elecsys Anti-SARS-CoV-2 per matrix and immunoglobulin**

377 **class**

	Number of results (Whole blood)				Number of results (EDTA Plasma)			
	IgM	**IgG**	**IgM+IgG**	**Total**	**IgM**	**IgG**	**IgM+IgG**	**Total**
SARS-CoV-2 positive (confirmed by Elecsys)	1	57	36	94	0	54	42	96
SARS-CoV-2 negative (confirmed by Elecsys)	0	0	0	264	0	0	0	265
False positive results (compared to Elecsys)	4	5	2	11	3	5	2	10
False negative results (compared to Elecsys)	0	0	0	6	0	0	0	4
OPA (95%CI)	95.47% (92.84–97.34)				96.27% (93.82–97.94)			
PPA (95% CI)	94.00% (87.40–97.77)				96.00% (90.07–98.90)			
NPA (95% CI)	96.00% (92.96–97.99)				96.36% (93.41–98.24)			

378 OPA, overall percentage agreement; PPA, positive percentage agreement; NPA, negative

379 percentage agreement

380 **Table 4a: Method comparison: Discrepant positive samples - detected signal intensity and immunoglobulin class**

Sample number	Rapid AB results – whole blood		Rapid AB results – EDTA plasma		Elecsys results (EDTA plasma)	
	IgG	**IgM**	**IgG**	**IgM**	**Result**	**COI**
1	-	X (weak)	-	X (weak)	Non-reactive	0.089
2	-	X (weak)	-	X (weak)	Non-reactive	0.119
3	-	X (weak)	-	X (weak)	Non-reactive	0.089
4	X (weak)	-	X (weak)	-	Non-reactive	0.079
5	-	X (weak)	-	-	Non-reactive	0.069
6	X (weak)	X (weak)	X (weak)	X (weak)	Non-reactive	0.229
7	X	-	X	-	Non-reactive	0.146
8	X (weak)	-	X (weak)	-	Non-reactive	0.221
9	X (weak)	-	X (weak)	-	Non-reactive	0.269
10	X	X	X	X	Non-reactive	0.189
11	X	-	X	-	Non-reactive	0.378

381 AB, antibody

382 **Table 4b Method comparison: Discrepant negative samples - detected signal intensity and immunoglobulin class**

Sample number	**Rapid AB results – whole blood**		**Rapid AB results – EDTA plasma**		**Elecsys results (EDTA plasma)**	
	IgG	IgM	IgG	IgM	Result	COI
1	-	-	-	-	Reactive	1.21
2	-	-	-	-	Reactive	1.99
3	-	-	X (weak)	-	Reactive	39.54
4	-	-	-	-	Reactive	2.32
5	-	-	-	-	Reactive	2.34
6	-	-	X (weak)	-	Reactive	16.7

383 AB, antibody

384

Figure 1. External method and matrix comparison – workflow